Threshold Pharmaceuticals (NASDAQ – THLD) has a targeted prodrug therapy solution used in conjunction with Gemzar® to determine OS and other endpoints in a segment of pancreatic cancer patients. The therapy is currently in Phase 2 clinical trials and investors are awaiting top-line results. We should note that THLD also has a drug in Phase 3 clinicals and has partnered with a major firm for development and licensing which could lead to over $550 in future payments.
Market Data 
Markets 
AI
